Discontinued — last reported Q4 '25
Business Segments · Impairment Charges
Biotechnology — Impairment Charges
Danaher Biotechnology — Impairment Charges decreased by 100.0% to $0 in Q4 2025 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryRisk
SignalLower is better
VolatilityVolatile
First reportedQ1 2023
Last reportedQ4 2025Feb 24, 2026
Rolls up toImpairment Charges
How to read this metric
An increase signals potential overvaluation of past acquisitions or deteriorating business prospects.
Detailed definition
Non-cash charges recognized when the carrying value of an asset or goodwill within the biotechnology segment exceeds its...
Peer comparison
Reported periodically by all public companies under GAAP/IFRS when asset values are tested.
Metric ID:
dhr_segment_biotechnology_impairment_chargesHistorical Data
10 periods
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $13.5M | $13.5M | $13.5M | $13.5M | $0 | $0 | $15M | $0 | $86M | $0 |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -100.0% | — | — | -100.0% | — | -100.0% |
| YoY Change | — | — | — | — | -100.0% | -100.0% | — | — | — | — |
Range$0 – $86M
CAGR-100.0%
Avg YoY Growth-100.0%
Median YoY Growth-100.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Danaher's biotechnology — impairment charges?
- Danaher (DHR) reported biotechnology — impairment charges of $0 in Q4 2025.
- What does biotechnology — impairment charges mean?
- A write-down of asset values due to a decline in their expected future worth.